SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

'We will continue to sell our patented drugs with India-specific pricing'

By 1 Comment

The Times of India

September 8, 2010

MSD India’s managing director KG Ananthakrishnan spoke to ET’s Khomba Singh on future strategy and shared his views on the Indian government’s proposals on contentious issues such as compulsory licensing, capping FDI in the sector and reviewing of certain sections of Indian patent laws. Excerpts:

Global drugmakers have lobbied hard for review of controversial Section 3(d) of Indian patent laws and patent linkages. MNCs, including Merck, are yet to publicly voice views on the proposal being evaluated by the government?

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

By 1 Comment

PubMed.gov

J Infect Dis. 2005 Jan 15;191(2):182-92. Epub 2004 Dec 10.

Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD.

Division of Infectious Diseases, Indiana University School of Medicine, 545 Barnhill Dr., Emerson Hall, Rm. 435, Indianapolis, IN 46202, USA. darbrow@iupui.edu
Abstract

BACKGROUND: We performed a study to better characterize the natural history of genital human papillomavirus (HPV) infection in a cohort of closely followed adolescent women.

METHODS: A cohort of 60 adolescent women was followed over a 2.2-year period, on average. A median of 41.5 self-collected vaginal and clinician-obtained cervical swabs were obtained from each subject.

Prevalence of high-risk human papillomavirus among older women

By 1 Comment

PubMed.gov

Obstet Gynecol. 2008 Nov;112(5):979-89.

Lindau ST, Drum ML, Gaumer E, Surawska H, Jordan JA.

University of Chicago Department of Obstetrics and Gynecology, the University of Chicago Cancer Research Center, Chicago, IL 60637, USA. slindau@uchicago.edu
Abstract

OBJECTIVE: To estimate the prevalence, genotypes, and individual-level correlates of high-risk human papillomavirus (HPV) among women aged 57-85.

METHODS: Community-residing women (N=1,550), aged 57-85, were drawn from a nationally representative probability sample. In-home interviews and biomeasures, including a self-collected vaginal specimen, were obtained between 2005 and 2006. Specimens were analyzed for high-risk HPV DNA using Hybrid Capture 2; of 1,028 specimens provided, 1,010 were adequate for analysis. All samples testing positive were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization.

Prevalence of HPV Infection Among Females in the United States

By 1 Comment

JAMA

Eileen F. Dunne, MD, MPH; Elizabeth R. Unger, PhD, MD; Maya Sternberg, PhD; Geraldine McQuillan, PhD; David C. Swan, PhD; Sonya S. Patel, BS; Lauri E. Markowitz, MD

JAMA. 2007;297:813-819.

ABSTRACT

Context – Human papillomavirus (HPV) infection is estimated to be the most common sexually transmitted infection. Baseline population prevalence data for HPV infection in the United States before widespread availability of a prophylactic HPV vaccine would be useful.

Objective – To determine the prevalence of HPV among females in the United States.

Design, Setting, and Participants – The National Health and Nutrition Examination Survey (NHANES) uses a representative sample of the US noninstitutionalized civilian population. Females aged 14 to 59 years who were interviewed at home for NHANES 2003-2004 were examined in a mobile examination center and provided a self-collected vaginal swab specimen. Swabs were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. Demographic and sexual behavior information was obtained from all participants.

Merck Cancer Shot May Not Be Economical for All Women (Update1)

By Leave a Comment

Bloomberg

By Shannon Pettypiece – August 21, 2008 10:18 EDT

Aug. 21 (Bloomberg) — Merck & Co.’s Gardasil cervical cancer vaccine isn’t worth the cost for women over 18 years old, according to a study that may undercut the drugmaker’s marketing efforts for that age group.

Gardasil, available for girls and young women ages 9 to 26, makes economic sense for preteens because they are less likely to have the sexually transmitted virus that causes cervical cancer, said researchers in a study released by the New England Journal of Medicine. Still, the cost benefit depends on how long Gardasil’s protection lasts, they said.

News

Videos

Contact